首页> 外文OA文献 >P2-252: Analyses of clinical prognostic factors in the treatment of advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients from three consecutive randomized Phase II trials using gemcitabine and docetaxel

【2h】

P2-252: Analyses of clinical prognostic factors in the treatment of advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients from three consecutive randomized Phase II trials using gemcitabine and docetaxel

机译：P2-252：晚期非小细胞肺癌（NSCLC）治疗的临床预后因素分析：基于吉西他滨和多西他赛的三项连续的随机II期试验的789名患者的Cox回归分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Eschbach Corinna; Pilz Lothar R.; Thatcher Nicholas; Kortsik Cornelius; Mezger Jörg; von Römer Kathrin Schott; Manegold Christian;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial [J] . D. Binder, H. Schweisfurth, C. Grah, Cancer Chemotherapy and Pharmacology . 2007,第1期

机译：多西他赛/吉西他滨或顺铂/吉西他滨再多西他赛在转移性非小细胞肺癌（NSCLC）患者的一线治疗中：一项多中心随机II期试验的结果
2. 1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1130 POSTER多西他赛/吉西他滨与序贯方案（包括顺铂/吉西他滨/多西他赛）在IV期非小细胞肺癌（NSCLC）患者的一线治疗中的比较：一项II期随机试验的结果
3. 1130 POSTER Docetaxel/gemcitabine vs. a sequential protocol comprising cisplatin/gemcitabine/docetaxel in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC): results of a randomised phase II trial [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1130 POSTER多西他赛/吉西他滨与序贯方案（包括顺铂/吉西他滨/多西他赛）在IV期非小细胞肺癌（NSCLC）患者的一线治疗中的比较：一项II期随机试验的结果
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer [O] . José Rodrigues Pereira, Rebecca Cheng, Mauro Orlando, -1

机译：培美曲塞加卡铂与多西他赛加卡铂作为一线治疗局部晚期或转移性非小细胞肺癌患者的随机III期研究的老年人亚组分析
7. P2-298: Report on three consecutive randomized phase II trials using single-agent docetaxel and gemcitabine in diferent doses and schedules for patients in advanced non-small cell lung cancer (NSCLC) [O] . Pilz Lothar R., Thatcher Nicholas, Kortsik Cornelius, 2007

机译：P2-298：针对晚期非小细胞肺癌（NSCLC）患者使用不同剂量和时间表的单药多西他赛和吉西他滨的三项连续的随机II期临床试验报告

P2-252: Analyses of clinical prognostic factors in the treatment of advanced non-small cell lung cancer (NSCLC): Cox regression analysis based on 789 patients from three consecutive randomized Phase II trials using gemcitabine and docetaxel

著录项

相似文献

相关主题

期刊订阅